Azithromycin: Single 1.5 g dose in the treatment of patients with atypical pneumonia syndrome. A randomized study

Infection

Volumn 27, Issue 3, 1999, Pages 198-202

  Schonwald S ^a   Kuzman, I ^a   Oreskovic K ^b   Burek, V ^a   Skerk V ^a   Car, V ^a   Bozinovic D ^a   Culig J ^b   Radosevic S ^b  

^a Croatia   (Croatia)

^b PLIVA CROATIA LTD   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHLAMYDOPHILA PNEUMONIAE; CHLAMYDOPHILA PSITTACI; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COXIELLA BURNETII; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LEGIONELLA PNEUMOPHILA; MAJOR CLINICAL STUDY; MALE; MYCOPLASMA PNEUMONIAE; ORAL DRUG ADMINISTRATION; OUTPATIENT CARE; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; RASH; SERODIAGNOSIS; SIDE EFFECT; URTICARIA; VOMITING;

ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; MALE; PNEUMONIA;

EID: 0033036979     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02561528     Document Type: Article

References (37)

1. 1. Levison, M. E.; Pneumonia, including necrotizing pulmonary infections (lung abscess). In: Isselbacher, K. J., Braunwald, E., Wilson, J. D., Martin, J. B., Fauci, A. S., Kasper, D. L. (eds.): Harrison's principles of internal medicine. McGraw-Hill, New York 1994, pp. 1184-1191.
2. 2. Donowitz, G. R., Mandell, G. L.: Acute pneumonia. In: Mandell, G. L., Bennett, J. E., Dolin, R. (eds.): Mandell, Douglas and Bennett's principles and practice of infectious diseases. Churchill Livingstone, New York 1995, pp. 619-637.
3. 3. Cunha, B. A., Ortega, A. M.: A typical pneumonia. Extrapulmonary clues guide the way to diagnosis. Postgrad. Med. 99 (1996) 123-132.
4. 4. Hoepelman, I. M., Schneider, M. M. E.: Azithromycin: the first of the tissue-selective azalides. Int. J. Antimicrob. Agents 5 (1995) 145-167.
5. 5. Renaudin, H., Bebear, C.: Comparative in vitro activity of azithromycin, clarithromycin, crythromycin and lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma arealyticum. Eur. J. Clin. Microbiol. Infect. Dis. 9 (1990) 838-841.
6. 6. Felmingham, D., Robbins, M. J., Sanghrajka, M., Leakey, A., Ridgway, G. L.: The in vitro activity of some 14-, 15- and 16-membered macrolides against Staphylococcus spp., Legionella spp., Mycoplasma spp, and Ureaplasma urealyticum. Drugs Exp. Clin. Res. 17 (1991) 91-99.
7. 7. Ishida, K., Kaku, M., Irifune, K., Mizukane, R., Takemura, H., Yoshida, R., Tanaka, H., Usui, T., Suyama, N., Tomono, K., Koga, H., Kohno, S., Izumikawa, K., Hara, K.: In vitro and in vivo activities of macrolides against Mycoplasma pneumoniae. Antimicrob. Agents Chemother. 38 (1994) 790-798.
8. 8. Niki, Y., Kimura, M., Miyashita, N., Soejima, R.; In vitro and in vivo activities of azithromycin, a new azalide antibiotic, against chlamydia. Antimicrob. Agents Chemother. 38 (1994) 2296-2299.
9. 9. Hammerschlag, M. R.: Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumoniae. Antimicrob. Agents Chemother. 38 (1994) 1873-1878.
10. 10. Welsh, L., Gaydos, C., Quinn, T. C.: In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains of Chlamydia pneumoniae. Antimicrob. Agents Chemother. 40 (1996) 212-214.
11. 11. Barry, A. L., Jones, R. N., Thornsberry, C.: In vitro activities of azithromycin (CP-62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin. Antimicrob. Agents Chemother. 32 (1988) 752-754.
12. 12. Johnson, D. M., Erwin, M. E., Barrett, M. S., Briggs Gooding, B., Jones, R. N.: Antimicrobial activity of ten macrolide, lincosamine and streptogramin drugs tested against Legionella species. Eur. J. Clin. Microbiol. Infect. Dis. 11 (1992) 751-755.
13. 13. Nimmo, G. R., Bull, J. Z.: Comparative susceptibility of Legionella pneumophila and Legionella longbacheae to 12 antimicrobial agents. J. Antimicrob. Chemother. 36 (1995) 219-223.
14. 14. Keysary, A., Itzhaki, A., Rubinstein, E., Oron, C., Keren, G.: The in vitro anti-rickettsial activity of macrolides. J. Antimicrob. Chemother. 38 (1996) 727-731.
15. 15. Foulds, G., Shepard, R. M., Johnson, R. B.: The pharmacokinetics of azithromycin in human serum and tissues. J. Antimicrob. Chemother. 25 (Suppl. A) (1990) 73-82.
16. 16. Morris, D. L., De Souza, A., Jones, J. A., Morgan, W. E.: High and prolonged pulmonary tissue concentrations of azithromycin following a single oral dose. Eur. J. Clin. Microbiol. Infect. Dis. 10 (1991) 859-861.
17. 17. Baldwin, D. R., Wise, R., Andrews, J. M., Ashby, J. P., Honeybourne, D.: Azithromycin concentrations at the sites of pulmonary infection. Eur. Respir. J. 3 (1990) 886-890.
18. 18. Schönwald, S., Gunjača, M., Kolačny-Babić, L., Car, V., Gošev, M.: Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias. J. Antimicrob. Chemother. 25 (Suppl. A) (1990) 123-126.
19. 19. Schönwald, S., Śkerk, V., Petričević, I., Car, V., Majerus-Mišić, Lj., Gunjača, M.: Comparison of three-day and five-day courses of azithromycin in the treatment of atypical pneumonia. Eur. J. Clin. Microbiol. Infect. Dis. 10 (1991) 877-880.
20. 20. Schönwald, S., Baršić, B., Klinar. I., Gunjača, M.: Three-day azithromycin compared with ten-day roxithromycin treatment of atypical pneumonia. Scand. J. Infect. Dis. 26 (1994) 706-710.
21. 21. Kuzman, I., Schönwald, S., Čulig, J., Orešković, K.: Azithromycin, erythromycin and doxycycline in the treatment of Mycoplasma pneumoniae pneumonia: a retrospective study. In: Berkarda, B. (ed.): 10th Mediterranean Congress of Chemotherapy. Monduzzi Editore, Bologna 1996. pp. 211-214.
22. 22. Kuzman, I., Orešković, K., Schönwald, S., Čulig, J.: Azithromycin in treatment of pneumonias caused by Chlamydia spp.: a retrospective study. Int. J. Clin. Pharm. Res. 16 (1997) 103-107.
23. 23. Kuzman, I., Soldo, I., Schönwald, S., Čulig, J.: Azithromycin for treatment of community-acquired pneumonia caused by Legionella pneumophila: a retrospective study. Scand. J. Infect. Dis. 27 (1995) 503-505.
24. 24. Bohte, R., van't Wout, J. W., Lobatto, S., Blussé van Oud Alblas, A., Boekhout, M., Nauta, E. H., Hermans, J., van den Brock, P. J.: Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia. Eur. J. Clin. Microbiol. Infect. Dis. 14 (1995) 182-187.
25. 25. Sočan, M.: Treatment of atypical pneumonia with azithromycin: comparison of a 5-day and a 3-day course. J. Chemother. 10 (1998) 64-68.
26. 26. Kuzman, I.: Community-acquired pneumonia: etiologic diagnosis and strategy of antibiotic therapy (doctoral thesis). Zagreb University, Zagreb 1994.
27. 27. Tartakovskii, I. S., Sinopalnikov, A. J., Martinova, V. R., Gorina, L. G., Komissarov, A. L., Rakov, A. J., Prosorovskii, S.V.: Community-acquired pneumonia: etiologic diagnosis and strategy of antibiotic therapy. In: Legionella infections and atypical pneumonias. Proceedings of the 11th meeting of the European Working Group on Legionella Infections, Oslo, Norway, 2-4 June 1996. The Norwegian Defence Microbiological Laboratory, Joint Medical Services, HQ Defense Command Norway, Oslo 1996, pp. 149-152.
28. 28. The Nordic Atypical Pneumonia Study Group: Atypical pneumonia in the Nordic countries: aetiology and clinical results of a trial comparing fleroxacin and doxycycline, J. Antimicrob. Chemother. 39 (1997) 499-508.
29. 29. Lieberman, D., Ben-Yaakov, M., Lazarovich, Z., Porath, A., Schaeffer, F., Lieberman, D., Leinonen, M., Saikku, P., Horovitz, O., Boldur, I.: Chlamydia pneumoniae community-acquired pneumonia: a review of 62 hospitalized adult patients. Infection 24 (1996) 109-114.
30. 30. Baum, S. G.: Mycoplasma pneumoniae and atypical pneumonia. In: Mandell, G. L., Bennett, J. E., Dolin, R. (eds.): Mandell, Douglas and Bennett's principles and practice of infectious diseases. Churchill Livingstone, New York 1995, pp. 1704-1713.
31. 31. Grajston. T. J.: Chlamydia pneumoniae (TWAR). In: Mandell, G. L., Bennett, J. E., Dolin, R. (eds.): Mandell, Douglas and Bennett's principles and practice of infectious diseases. Churchill Livingstone, New York 1995, pp. 1696-1701.
32. 32. Stout, J. E., Yu, V. L.: Legionellosis. N. Engl. J. Med. 337 (1997) 682-687.
33. 33. Marrie, T. J.: Coxiella burnetii (Q fever). In: Mandell, G. L., Bennett, J. E., Dolin, R. (eds.): Mandell, Douglas and Bennett's principles and practice of infectious diseases. Churchill Livingstone, New York 1995, pp. 1727-1735.
34. 34. Fitzgeorge, R. B., Featherstone, A. S. R., Baskerville, A.: Efficacy of azithromycin in the treatment of guinea pigs infected with Legionella pneumophila by aerosol. J. Antimicrob. Chemother. 25 (Suppl. A) (1990) 101-108.
35. 35. Fitzgeorge, R. B., Lever, S., Baskerville, A.: A comparison of the efficacy of azithromycin and clarithromycin in oral therapy of experimental airborne legionnaires' disease. J. Antimicrob. Chemother. 31 (Suppl. E) (1993) 171-176.
36. 36. Malinverni, R., Kuo, C. C., Campbell, L. A., Lee, A., Grayston, J. T.: Effects of two antibiotic regimens on course and persistence of experimental Chlamydia pneumoniae TWAR pneumonitis. Antimicrob. Agents Chemother. 39 (1995) 45-49.
37. 37. Cunha, B. A.: The antibiotic treatment of community-acquired, atypical, and nosocomial pneumonias. Med. Clin. North Am. 79 (1995) 581-597.